Amgen 2011 Annual Report Download - page 90
Download and view the complete annual report
Please find page 90 of the 2011 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80 -
81 -
82 -
83 -
84 -
85 -
86 -
87 -
88 -
89 -
90 -
91 -
92 -
93 -
94 -
95 -
96 -
97 -
98 -
99 -
100 -
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117
-
118
-
119
-
120
-
121
-
122
-
123
-
124
-
125
-
126
-
127
-
128
-
129
-
130
-
131
-
132
-
133
-
134
-
135
-
136
-
137
-
138
-
139
-
140
-
141
-
142
-
143
-
144
-
145
-
146
-
147
-
148
-
149
-
150
-
151
-
152
-
153
-
154
-
155
-
156
-
157
-
158
-
159
-
160
-
161
-
162
-
163
-
164
-
165
-
166
-
167
-
168
-
169
-
170
-
171
-
172
-
173
-
174
-
175
-
176
-
177
-
178
-
179
-
180
-
181
-
182
-
183
-
184
 |
 |
Aranesp®
Total Aranesp®sales by geographic region were as follows (dollar amounts in millions):
2011 Change 2010 Change 2009
Aranesp®—U.S. ....................................... $ 986 (11)% $1,103 (12)% $1,251
Aranesp®— International ................................. 1,317 (5)% 1,383 (1)% 1,401
Total Aranesp®..................................... $2,303 (7)% $2,486 (6)% $2,652
The decrease in U.S. Aranesp®sales for 2011 was due principally to a high-teens percentage point unit
decline, offset partially by an increase in the average net sales price. The unit decline reflects segment
contraction resulting from changes to reimbursement in 2011 and the June 2011 ESA label changes. The decrease
in international Aranesp®sales for 2011 was due to a decrease in the average net sales price and a unit decline,
reflecting segment contraction.
The decrease in U.S. Aranesp®sales for 2010 was due primarily to a unit decline, reflecting segment
contraction. The decrease in international Aranesp®sales for 2010 was due primarily to a unit decline.
In addition to other factors mentioned in the Product sales section above, future Aranesp®sales will depend,
in part, on such factors as:
• regulatory developments, including the June 2011 ESA label changes and any other product label
changes;
• reimbursement developments, including LCDs;
• changes in dose utilization as healthcare providers continue to refine their treatment practices in
accordance with approved labeling; and
• development of new protocols, tests and/or treatments for cancer and/or new chemotherapy treatments or
alternatives to chemotherapy that may have reduced and may continue to reduce the use of chemotherapy
in some patients.
Certain of the above factors may have a material adverse impact on future sales of Aranesp®.
See Item 1. Business — Significant Developments, Item 1. Business — Marketed Products and Item 1A.
Risk Factors for further discussion of certain of the above factors that could impact our future product sales.
EPOGEN®
Total EPOGEN®sales were as follows (dollar amounts in millions):
2011 Change 2010 Change 2009
EPOGEN®—U.S. ...................................... $2,040 (19)% $2,524 (2)% $2,569
The decrease in EPOGEN®sales for 2011 was due primarily to a decrease in dose utilization related to
changes to reimbursement in 2011 and the June 2011 ESA label changes, offset partially by an increase in the
average net sales price and patient population growth.
The decrease in EPOGEN®sales for 2010 was due primarily to a unit decline and certain changes in
accounting estimates. The unit decline reflects a decrease in dose utilization, offset partially by patient population
growth.
74